![腾博会官网·[中国]-诚信为本,专业服务!
制药英文站](http://zhengzhoujiaobanji.com/userfiles/images/banner/sinologo.png)
Investors
Information Disclosure
-
2024 INTERIM REPORT2024.09.26
-
NOTIFICATION LETTER AND REPLY FORM FOR REGISTERED HOLDERS2024.09.26
-
NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED HOLDERS2024.09.26
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "RIVASTIGMINE TRANSDERMAL PATCH"2024.09.25
-
VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF ANLOTINIB HYDROCHLORIDE CAPSULES IN COMBINATION WITH BENMELSTOBART INJECTION FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA WAS PRESENTED AT ESMO 20242024.09.16
-
VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF ANLOTINIB HYDROCHLORIDE CAPSULES IN COMBINATION WITH PENPULIMAB INJECTION FOR FIRST-LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA WAS PRESENTED AT ESMO 20242024.09.16
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 20242024.09.02
-
VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF HR+/HER2- ADVANCED BREAST CANCER FOLLOWING ENDOCRINE TREATMENT TO BE PRESENTED AT 2024 CSCO2024.08.29